

Edgar Filing: Cytosorbents Corp - Form 8-K

Cytosorbents Corp  
Form 8-K  
January 11, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2013

CYTOSORBENTS CORPORATION  
(Exact name of registrant as specified in its charter)

Nevada                      000-51038    98-0373793

(State or other jurisdiction (Commission (IRS Employer  
of incorporation)              File Number) Identification No.)

7 Deer Park Drive, Suite K

Monmouth Junction, New Jersey              08852

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 329-8885

Edgar Filing: Cytosorbents Corp - Form 8-K

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Cytosorbents Corporation (the “Company”) issued a letter to its shareholders on January 9, 2013 summarizing the Company’s achievements in 2012 and the Company’s goals for 2013. A copy of the letter is being furnished as Exhibit 99.1 hereto.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description of Exhibit
99.1	“Shareholder letter issued on January 9, 2013” The Shareholder letter is furnished and not filed pursuant to Instruction B.2 of Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoSorbents Corporation

Date: January 11, 2013 By: /s/ Dr. Phillip P. Chan

Edgar Filing: Cytosorbents Corp - Form 8-K

Name: Dr. Phillip P. Chan

Title: President and CEO